Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
Correction notice of press release - Q3 2020 Interim Report - ZUBSOLV® guiding 2020 PR Newswire UPPSALA, Sweden, Nov. 4, 2020 UPPSALA, Sweden , Nov. 4, 2020 /PRNewswire/ -- (STO:ORX) (OTCQX:ORXOY) In connection with the publication of the Interim Rep...
Orexo Interim Report Q3 2020 The new future starts to take shape PR Newswire UPPSALA, Sweden, Nov. 4, 2020 UPPSALA, Sweden , Nov. 4, 2020 /PRNewswire/ -- Q3 2020 highlights Total net revenues of SEK 150.3 m (231.2), 189.7 excluding Abstr...
Orexo and Lyfebulb Announce the Winner of the 2020 Innovation Challenge in Substance Use Disorders PR Newswire UPPSALA, Sweden and NEW YORK, Oct. 15, 2020 UPPSALA, Sweden and NEW YORK , Oct. 15, 2020 /PRNewswire/ -- Orexo, a Swedish pharmaceutical co...
Orexo´s Nomination Committee for the Annual General Meeting 2021 PR Newswire UPPSALA, Sweden, Oct. 13, 2020 UPPSALA, Sweden , Oct. 13, 2020 /PRNewswire/ -- Prior to the Annual General Meeting (AGM) in 2021, Orexo has appointed a Nomination Committee...
Invitation - Orexo Digital Therapeutics business update October 1 PR Newswire UPPSALA, Sweden, Sept. 25, 2020 UPPSALA, Sweden , Sept. 25, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts, and media to atte...
Orexo AB ( OTCQX:ORXOY ) files a patent infringement action against Sun Pharmaceutical for selling generic versions of ZUBSOLV® products in the US. More news on: Orexo AB (publ), Healthcare stocks news, Read more ...
Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and ind...
UPPSALA, Sweden , Sept. 14, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has filed a patent infringement action in the United States District Court for the District of New Jersey with docket number 3:20-cv-12588, against Sun Pharmaceutical I...
MORRISTOWN, N.J. , Sept. 9, 2020 /PRNewswire/ -- Orexo and GoGoMeds have formed a partnership to make the scientifically-proven, digital therapies deprexis® and vorvida® available for the treatment of depression and management of problematic alcohol misuse respectively. OXD...
UPPSALA, Sweden and NEW YORK , Sept. 1, 2020 /PRNewswire/ -- Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, announced the 10 Patient Entrepreneurs selected as finalists for the Lyfebulb and...
News, Short Squeeze, Breakout and More Instantly...
Orexo Q2 2024 Interim Report PR Newswire UPPSALA, Sweden , July 17, 2024 /PRNewswire/ -- Making progress, while the OX124 review time extended Q2 2024 highlights Total net revenues of SEK 154.0 m (157.7) EBITDA of SEK 5.0 m (5.6)...
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose PR Newswire UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received...
Orexo AB´s sustainability work ranked among top 5% by EcoVadis PR Newswire UPPSALA, Sweden , July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the...